度洛西汀用于术后急性镇痛的随机试验荟萃分析
该荟萃分析纳入9项随机对照试验共574例患者,评估围术期度洛西汀对比安慰剂对术后急性疼痛的疗效。结果显示度洛西汀在术后4小时至48小时显著降低疼痛评分,减少24小时和48小时阿片类药物用量,并降低术后恶心呕吐发生率,其他副作用无差异。
要点
- 度洛西汀可显著降低术后4至48小时疼痛评分。
- 度洛西汀减少术后24小时和48小时阿片类药物用量。
- 度洛西汀降低术后恶心呕吐风险,其他副作用无差异。
核心结论
- 度洛西汀作为非阿片类神经调节剂,可能对术后急性疼痛治疗有效。
- 需进一步前瞻性研究确定最佳围术期给药方案及其在多模式镇痛中的角色。
研究设计与样本
- 荟萃分析纳入9项随机对照试验,共574例患者,度洛西汀组285例,安慰剂组289例。
- 检索PubMed、EMBASE和Google Scholar数据库,比较度洛西汀与安慰剂对术后急性疼痛的疗效。
主要发现
- 术后4小时疼痛评分平均差异为-0.9(95%CI -1.33至-0.47),术后48小时为-0.94(95%CI -1.56至-0.33),均显著低于安慰剂组。
- 术后24小时阿片类药物用量标准化平均差异为-2.24(95%CI -4.28至-0.19),48小时为-2.21(95%CI -4.13至-0.28),均显著减少。
- 术后恶心呕吐风险比为0.69(95%CI 0.49至0.95,p=0.03),显著低于安慰剂组。
- 其他副作用(瘙痒、头晕、头痛)两组间无差异。
临床怎么用
- 围术期可考虑使用度洛西汀作为多模式镇痛辅助,以减轻术后疼痛和阿片类药物用量。
- 需注意最佳给药方案尚未确定,应个体化评估获益与风险。
局限性
- 需更多前瞻性研究确定最佳围术期给药方案。
- 度洛西汀在多模式镇痛方案中的角色及对慢性术后疼痛的影响尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multimodal analgesia is a fundamental part of modern surgery and enhanced recovery pathways. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has been validated for the treatment of chronic neuropathic pain. The evidence for duloxetine as an adjunct for the treatment of acute postoperative pain remains controversial. We conducted a meta-analysis to determine the efficacy of duloxetine in the acute perioperative setting. METHODS: A literature search was conducted in the major databases (PubMed, EMBASE and Google Scholar) for randomized controlled trials (RCTs) evaluating duloxetine compared with placebo control for acute postoperative pain. The primary outcome was postoperative pain assessed at 2, 4, 6, 24 and 48 hours time frames. Secondary outcomes included postoperative opioid administration, as well as side effects, such as postoperative nausea/vomiting (PONV), pruritus, dizziness and headache. RESULTS: 574 patients (n=9 RCTs) were included in the analysis, divided between duloxetine (n=285 patients) and placebo (n=289 patients). Duloxetine use was associated with a significant reduction in pain scores as early as 4 (mean difference (MD) -0.9, 95% CI -1.33 to -0.47) and as late as 48 (MD -0.94, 95% CI -1.56 to -0.33) hours postoperatively compared with placebo. In addition, duloxetine was associated with a significant reduction in opioid administration at 24 (standardized MD (SMD) -2.24, 95% CI -4.28 to -0.19) and 48 (SMD -2.21, 95% CI -4.13 to -0.28) hours as well as a significant reduction in PONV (risk ratio 0.69, 95% CI 0.49 to 0.95, p=0.03) compared with placebo. There was no difference between groups in other side effects. CONCLUSION: Duloxetine, a non-opioid neuromodulator, may provide efficacy for the treatment of acute perioperative pain. Additional prospective studies are required to establish optimal perioperative dosing regimens, role in the setting of a comprehensive multimodal analgesic plan and impact on chronic postsurgical pain. PROSPERO REGISTRATION NUMBER: CRD42019121416.
引用
- Zorrilla-Vaca A, Stone A, Caballero-Lozada AF, et al. Perioperative duloxetine for acute postoperative analgesia: a meta-analysis of randomized trials. Reg Anesth Pain Med. 2019. PMID: 31375539. doi:10.1136/rapm-2019-100687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。